A research team of scientists from the Fraunhofer IPA, the Bosch Digital Innovation Hub at Bosch Health Campus and the Institute of Image-Guided Surgery (IHU) of Strasbourg has jointly launched the DAIOR project. Within the framework of the project, the project partners are working on realizing the operating room of the future with help of artificial intelligence and robot assisted telemedicine.

Project SMARTGAIT - 13/09/2023

Safe and cost-effective analysis of neurological gait disorders with AI

Stroke, Parkinson's disease and multiple sclerosis often resulting in gait disorders in those affected. Gait analyses play a crucial role in the successful evaluation and therapy of such disorders. Current measurement methods are costly and time-consuming. The SMARTGAIT project is therefore developing an innovative AI-based system aimed at performing meaningful gait analyses with the help of simple smartphone video recordings.

DNA nanotechnology - 25/08/2023

Artificial cytoskeleton made of DNA for synthetic cells

The physicists Prof. Dr. Kerstin Göpfrich and Prof. Dr. Laura Na Liu want to understand life from the bottom up. They intend to do this by constructing an artificial cell. However, rather than natural protein building blocks, they are using 3D-DNA structures as construction material. The first step involved creating an artificial cell skeleton that dynamically assembles and disassembles like the biological model and can transport vesicles.

Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples. The algorithm can help physicians diagnose blood disorders and is available as an open source method for research purposes.

NeuroQ project - 26/07/2023

Quantum sensors for exoskeletons: can quantum physics beat paralysis?

Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.

So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state.

Rejuvenating skin and preventing skin cancer: That is the vision of the scientists at the new Joint Innovation Lab, which Beiersdorf and the German Cancer Research Center (DKFZ) founded on July 1, 2023. In the jointly operated lab, researchers are taking a close look at the "epigenetic clock" of skin cells with the aim of turning back biological aging and thus also reducing the risk of skin cancer.

KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.

The AutoProNano German/French collaborative project involves developing a process for the automated production of nanoparticles for in vitro and in vivo diagnostics. The project is being launched within the smart analytics cooperation network. This international initiative has been funded by the Central Innovation Programme for SMEs (ZIM) of the German Federal Ministry for Economic Affairs and Climate Action (BMWK) since May 2020.

Detecting drug resistance of tumour cells - 25/05/2023

AI-assisted diagnostics declares war on lung cancer

Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.

Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.

Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates. Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains.

Expert interview - 08/03/2023

How do new active substances from university research reach patients?

Access to capital remains one of the biggest challenges in the life sciences sector. Over the last two years, the Baden-Württemberg Center for Academic Drug Discovery (BWCAD2) has successfully implemented a model of cooperation between academic drug research and industry for the development and validation of therapeutic concepts. Dr. Barbara Jonischkeit spoke with the initiator and leading figure behind the BWCAD2 project, Prof. Dr. Stefan Laufer

Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.

Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

Non-profit limited liability company creates institutional framework for interdisciplinary research collaboration, innovative technology development and outstanding healthcare in the Rhine-Neckar region.

Photon-counting technology - 01/02/2023

PC3 consortium: innovative computed tomography for Baden-Württemberg

The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.

Automated pain recognition - 25/01/2023

Using artificial intelligence to improve pain management

Psychologists from Ulm and their cooperation partners have developed algorithms for automated pain recognition in order to be able to dose painkillers more precisely. The researchers are now looking for industrial partners to take their project to application.

Heidelberg scientists succeed in boosting the efficiency of CRISPR/Cas9 and related methods and modifying initially inaccessible DNA sequences.

Mitochondria are considered to be the power plants of cells and are essential for human metabolism. Dysfunction in 40 percent of mitochondrial proteins are associated with human diseases, which is why mitochondria also play an important role in medical research. A previously unexplained process in the complex mitochondria was the formation of their barrel pores.

In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

BioFluidix GmbH, a spin-off resulting from the cooperation between Hahn-Schickard and the Department of Microsystems Engineering at the University of Freiburg, is now part of the Swiss Hamilton Bonaduz AG.